Abstract
Psoriatic arthritis (PsA) is an inflammatory arthropathy associated with skin and/or nail psoriasis. TNF-α, in addition to its pro-inflammatory role, is an essential cytokine for the host's defense, and its depletion by treatment may facilitate the risk of viral infections or their reactivation. The aim of this study was to evaluate the efficacy and safety of TNF-α blockers in PsA patients with concurrent hepatitis C virus (HCV) infection. This is a multicenter study carried out in four Italian centers specialized in the diagnosis and treatment of PsA. At baseline and after 6 (T6) and 12 months (T12) of therapy, data concerning PsA activity and liver tests were registered. A total of 15 PsA patients with concomitant HCV infection were included in the study. At baseline, 13 patients had low viral load, and liver enzyme tests were within the normal range. During the observation period, these values remained stable. On the other hand, at baseline, a high viral load with slightly increased values of AST and ALT was detected in one patient. At T6 and T12, these values decreased. The remaining patient, at baseline, had low viral load, but with slightly increased AST and ALT values that normalized during the observation period. This is the greatest sample size available in the literature on this topic. The data suggests that anti-TNF-α agents are effective and safe in PsA patients with concomitant HCV. We suggest that the use of anti-TNF-α agents, accompanied by close monitoring, could be a therapeutic option.
Similar content being viewed by others
References
Moll JM, Wright V (1973) Psoriatic arthritis. Semin Arthritis Rheum 3:55–78
Scarpa R, Manguso F, D'Arienzo A, D'Armiento FP, Astarita C, Mazzacca G, Ayala F (2000) Microscopic inflammatory changes in colon of patients with both active psoriasis and psoriatic arthritis without bowel symptoms. J Rheumatol 27:1241–1246
Costa L, Caso F, D'Elia L, Atteno M, Peluso R, Del Puente A, Strazzullo P, Scarpa R (2012) Psoriatic arthritis is associated with increased arterial stiffness in the absence of known cardiovascular risk factors: a case control study. Clin Rheumatol 31:711–715
Scarpa R, Atteno M, Lubrano E, Provenzano G, D'Angelo S, Spadaro A, Costa L, Olivieri I (2011) The effectiveness and safety of TNF-alpha blockers in the treatment of early psoriatic arthritis: an Italian multicentre longitudinal observational pilot study. Clin Rheumatol 30:1063–1067
Punzi L, Podswiadek M, Sfriso P, Oliviero F, Fiocco U, Todesco S (2007) Pathogenetic and clinical rationale for TNF-blocking therapy in psoriatic arthritis. Autoimmun Rev 6:524–528
Modesti V, Ramonda R, Ortolan A, Lorenzin M, Lo Nigro A, Frallonardo P, Oliviero F, Campana C, Punzi L (2012) Infection relapse in spondyloarthritis treated with biological drugs: a single-centre study. Scand J Rheumatol 41:490–491
Fabris P, Baldo V, Baldovin T, Bellotto E, Rassu M, Trivello R, Tramarin A, Tositti G, Floreani A (2008) Changing epidemiology of HCV and HBV infections in Northern Italy: a survey in the general population. J Clin Gastroenterol 42:527–532
Cavazzana I, Ceribelli A, Cattaneo R, Franceschini F (2008) Treatment with etanercept in six patients with chronic hepatitis C infection and systemic autoimmune diseases. Autoimmun Rev 8:104–106
Rokhsar C, Rabhan N, Cohen SR (2006) Etanercept monotherapy for a patient with psoriasis, psoriatic arthritis, and concomitant hepatitis C infection. J Am Acad Dermatol 54:361–362
Magliocco MA, Gottlieb AB (2004) Etanercept therapy for patients with psoriatic arthritis and concurrent hepatitis C virus infection: report of 3 cases. J Am Acad Dermatol 51:580–584
Aslanidis S, Vassiliadis T, Pyrpasopoulou A, Douloumpakas I, Zamboulis C (2007) Inhibition of TNFalpha does not induce viral reactivation in patients with chronic hepatitis C infection: two cases. Clin Rheumatol 26:261–264
Calabrese LH, Zein N (2007) Biologic agents and liver toxicity: an added concern or therapeutic opportunity? Nat Clin Pract Rheumatol 3:422–423
Salvarani C, Olivieri I, Pipitone N, Cantini F, Marchesoni A, Punzi L, Scarpa R, Matucci-Cerinic M; Italian Society for Rheumatology (2011) Recommendations for the use of biologic therapy in the treatment of psoriatic arthritis: update from the Italian Society for Rheumatology. Clin Exp Rheumatol 29:S28–S41
Park J, Kang W, Ryu SW, Kim WI, Chang DY, Lee DH, do Park Y, Choi YH, Choi K, Shin EC, Choi C (2012) Hepatitis C virus infection enhances TNFα-induced cell death via suppression of NF-κB. Hepatology 56:831–840
Suryaprasad AG, Prindiville T (2003) The biology of TNF blockade. Autoimmun Rev 2:346–357
Tilg H, Wilmer A, Vogel W, Herold M, Nölchen B, Judmaier G, Huber C (1992) Serum levels of cytokines in chronic liver diseases. Gastroenterology 103:264–274
Freeman AJ, Marinos G, Ffrench RA, Lloyd AR (2001) Immunopathogenesis of hepatitis C virus infection. Immunol Cell Biol 79:515–536
Larrea E, Garcia N, Qian C, Civeira MP, Prieto J (1996) Tumor necrosis factor alpha gene expression and the response to interferon in chronic hepatitis C. Hepatology 23:210–217
Aletaha D, Kapral T, Smolen JS (2003) Toxicity profiles of traditional disease modifying antirheumatic drugs for rheumatoid arthritis. Ann Rheum Dis 62:482–486
Galeazzi M, Bellisai F, Giannitti C, Manganelli S, Morozzi G, Sebastiani GD (2007) Safety of cyclosporin A in HCV-infected patients: experience with cyclosporin A in patients affected by rheumatological disorders and concomitant HCV infection. Ann N Y Acad Sci 1110:544–549
Disclosures
None.
Author information
Authors and Affiliations
Corresponding author
Additional information
Luisa Costa and Francesco Caso equally contributed to this study.
Rights and permissions
About this article
Cite this article
Costa, L., Caso, F., Atteno, M. et al. Long-term safety of anti-TNF-α in PsA patients with concomitant HCV infection: a retrospective observational multicenter study on 15 patients. Clin Rheumatol 33, 273–276 (2014). https://doi.org/10.1007/s10067-013-2378-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-013-2378-0